TP53
Y220C is a rare genomic alteration (GA) with emerging targeted therapies. However, its prevalence in breast cancer remains undefined. We evaluated the prevalence of the Y220C alteration and association with other GAs.
A total of 23,760 patients with advanced breast cancer were analyzed by hybrid ca...
N. Casasanta, Adriana M. Kahn, N. Fischbach et al.· JCO Oncology Advances· 0 citations
These findings support comprehensive genomic profiling to identify ALK fusions in CRC, which may inform the use of ALK-directed therapies, and highlight the frequent co-occurrence of MSI-high disease within this subgroup.
Xuan-Yi Li, Faiza Yasin, D. Pavlick et al.· The Oncologist· 0 citations
Despite shared genomic drivers with PDAC, ASQ exhibits transcriptionally distinct features with spatially organized tumor and immune heterogeneity, supporting the need for subtype-specific therapeutic strategies.
S. Haldar, Meredith Wetzel, Jia-Yun Lu et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.